CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05104463
NCT05104463Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Effects of CST-2032 and CST-107 on Cognition in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

CuraSen Therapeutics, Inc.·interventional·Posted Nov 3, 2021·Updated Jan 23, 2025

In Brief

A Phase 2 clinical trial evaluating CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 for Mild Cognitive Impairment and Dementia. Completed, enrolled 64 participants across 15 sites in 2 countries.

Detailed Summary

This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Dementia
CountriesNew Zealand, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 3, 2021
Enrollment StartApr 11, 2022
Primary CompletionDec 20, 2023
Study CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.7 years ago

Interventions

CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107drug

CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets